U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H34ClN2O8PS
Molecular Weight 504.963
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN PHOSPHATE

SMILES

[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]2([H])O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

InChIKey=UFUVLHLTWXBHGZ-MGZQPHGTSA-N
InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H34ClN2O8PS
Molecular Weight 504.963
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN T

Approved Use

Clindamycin Phosphate is indicated in the treatment of acne vulgaris.

Launch Date

3.31862409E11
Curative
CLEOCIN PHOSPHATE

Approved Use

Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.

Launch Date

8.6745596E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.92 ng/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.2 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.54 ng × h/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources: Page: p.571
unhealthy, 16 - 51
n = 79
Health Status: unhealthy
Condition: Bacterial Vaginosis
Age Group: 16 - 51
Sex: F
Population Size: 79
Sources: Page: p.571
Disc. AE: Vaginal pain or burning...
AEs leading to
discontinuation/dose reduction:
Vaginal pain or burning (1.2%)
Sources: Page: p.571
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Reaction skin (severe)
Toxic epidermal necrolysis (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Vaginal pain or burning 1.2%
Disc. AE
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources: Page: p.571
unhealthy, 16 - 51
n = 79
Health Status: unhealthy
Condition: Bacterial Vaginosis
Age Group: 16 - 51
Sex: F
Population Size: 79
Sources: Page: p.571
Anaphylactic shock Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Toxic epidermal necrolysis grade 3-5
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Reaction skin severe
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5.0
minor
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5.0
not determined
not determined
not determined
not determined
not determined
not determined
not determined
not determined
PubMed

PubMed

TitleDatePubMed
A simple, efficient and inexpensive program for preventing prematurity.
2001
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
2001
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.
2001 Apr
Chronic granulomatous disease: a case report.
2001 Apr
Thoracic spondylitis mimicking idiopathic scoliosis: a case report.
2001 Apr
Activation of clindamycin phosphate by human skin.
2001 Apr
Clindamycin suspension and endocarditis prophylaxis.
2001 Apr 28
Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors.
2001 Feb
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
2001 Feb
A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris.
2001 Feb
Dermatopharmacology of a new combination gel formulation for the topical treatment of acne.
2001 Feb
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
Folliculitis decalvans.
2001 Jan
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.
2001 Jan
Emerging erythromycin resistance among group B streptococci in Korea.
2001 Jan
Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore.
2001 Jan
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product.
2001 Jan-Feb
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents.
2001 Jul
A rare case of primary group A streptococcal peritonitis.
2001 Jul
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads.
2001 Jul
Cutaneous botryomycosis of the cervicofacial region.
2001 Jul
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.
2001 Jun
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.
2001 Jun
Eikenella corrodens: an unusual cause of severe parapneumonic infection and empyema in immunocompetent patients.
2001 Jun
Bilateral peritonsillar abscess: case report and presentation of its clinical appearance.
2001 Jun
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada.
2001 Jun 12
Infection of hamsters with epidemiologically important strains of Clostridium difficile.
2001 Jun 15
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
2001 Jun 25
Antibiotic susceptibility of Clostridium difficile isolates from adult patients at two Jamaican hospitals. Clinical and epidemiological implications.
2001 Mar
[Ocular parasitoses and mycoses: cases diagnosed in the Central University Hospital of Sfax between 1996 and 1999].
2001 Mar
Prevalence and phenotypes of erythromycin-resistant Streptococcus pneumoniae in Shanghai, China.
2001 Mar
A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis.
2001 Mar
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy.
2001 Mar
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis].
2001 Mar
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
2001 Mar
Detection and characterization of a bacteriocin, garviecin L1-5, produced by Lactococcus garvieae isolated from raw cow's milk.
2001 Mar
Tufted hair folliculitis after scalp injury.
2001 Mar
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
2001 Mar
[Dermo-hypodermitis and necrotizing fasciitis].
2001 Mar 31
The treatment of babesiosis.
2001 Mar 8
Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan.
2001 May
Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice.
2001 May
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women?
2001 May
Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures.
2001 May
Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial.
2001 May
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.
2001 May
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
Erythromycin and amoxicillin?
2001 Winter
Patents

Sample Use Guides

150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:50:27 UTC 2023
Edited
by admin
on Wed Jul 05 22:50:27 UTC 2023
Record UNII
EH6D7113I8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLINDAMYCIN PHOSPHATE
EP   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN  
Official Name English
DUAC COMPONENT CLINDAMYCIN PHOSPHATE
Common Name English
CLINDETS
Brand Name English
XACIATO
Brand Name English
ACANYA COMPONENT CLINDAMYCIN PHOSPHATE
Common Name English
BENZACLIN COMPONENT CLINDAMYCIN PHOSPHATE
Common Name English
CLINDA-DERM
Brand Name English
CLINDAMYCIN PHOSPHATE [USP-RS]
Common Name English
CLINDAC
Brand Name English
CLINDAMYCIN PHOSPHATE [USP MONOGRAPH]
Common Name English
CLINDAMYCIN PHOSPHATE [WHO-IP]
Common Name English
Clindamycin phosphate [WHO-DD]
Common Name English
CLINDESSE
Brand Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, 2-(DIHYDROGEN PHOSPHATE), (2S-TRANS)-
Common Name English
CLEOCIN PHOSPHATE
Brand Name English
CLINDAMYCINI PHOSPHAS [WHO-IP LATIN]
Common Name English
CLINDAMYCIN PHOSPHATE [EP MONOGRAPH]
Common Name English
NSC-618653
Code English
CLINDAMYCIN PHOSPHATE [MART.]
Common Name English
CLINDAGEL
Brand Name English
DALACIN T
Brand Name English
U-28,508
Code English
CLINDAMYCIN PHOSPHATE [USAN]
Common Name English
U-28508
Code English
CLINDAMYCIN PHOSPHATE [VANDF]
Common Name English
ZIANA COMPONENT CLINDAMYCIN PHOSPHATE
Common Name English
VELTIN COMPONENT CLINDAMYCIN PHOSPHATE
Brand Name English
CLINDAMYCIN PHOSPHATE COMPONENT OF VELTIN
Brand Name English
CLINDAMYCIN PHOSPHATE [ORANGE BOOK]
Common Name English
CLINDAMYCIN PHOSPHATE [JAN]
Common Name English
CLINDAMYCIN (AS PHOSPHATE)
Common Name English
CLINDAMYCIN 2-DIHYDROGEN PHOSPHATE
MI  
Common Name English
CLINDAMYCIN PHOSPHATE COMPONENT OF ZIANA
Common Name English
IDP-126 COMPONENT CLINDAMYCIN PHOSPHATE
Code English
EVOCLIN
Brand Name English
CLINDAMYCIN PHOSPHATE COMPONENT OF BENZACLIN
Common Name English
7(S)-CHLORO-7-DEOXYLINCOMYCIN 2-PHOSPHATE
Common Name English
METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE 2-(DIHYDROGEN PHOSPHATE)
Common Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-((((2S,4R)-1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, 2-(DIHYDROGEN PHOSPHATE)
Systematic Name English
CLINDAMYCIN PHOSPHATE COMPONENT OF ACANYA
Common Name English
CLINDAMYCIN PHOSPHATE SYSTEM SUITABILITY [USP-RS]
Common Name English
CLINADAC
Brand Name English
CLEOCIN
Brand Name English
CLINDAMYCIN 2-PHOSPHATE
Common Name English
CLINDAMYCIN PHOSPHATE COMPONENT OF DUAC
Common Name English
CLINDAMYCIN 2-DIHYDROGEN PHOSPHATE [MI]
Common Name English
CLINDAMYCIN PHOSPHATE HYDRATE [JAN]
Common Name English
CLEOCIN T
Brand Name English
CLINDAMYCIN PHOSPHATE HYDRATE
JAN  
Official Name English
U 28508
Code English
DALACIN P
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C82922
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
Code System Code Type Description
RXCUI
797272
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID1048677
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
ECHA (EC/EINECS)
246-433-0
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
PUBCHEM
443385
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
FDA UNII
EH6D7113I8
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
JAPANESE REVIEW
DUAC
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY APPROVED MARCH 2015
ChEMBL
CHEMBL3184512
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
RS_ITEM_NUM
1138008
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
CAS
24729-96-2
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
NSC
618653
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
SMS_ID
100000090555
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
DAILYMED
EH6D7113I8
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
EVMPD
SUB01344MIG
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
NCI_THESAURUS
C47978
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
DRUG BANK
DBSALT000778
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
MERCK INDEX
M3624
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
CLINDAMYCIN PHOSPHATE
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY Description: A white or almost white, crystalline powder.Solubility: Freely soluble in water; very slightly soluble in ethanol (~750 g/l) TS and acetone R.Category: Antibacterial drug.Storage: Clindamycin phosphate should be kept in a tightly closed container.Labelling: The designation Clindamycin phosphate for parenteral use indicates that the substance complies with the additionalrequirements and may be used for parenteral administration. Expiry date.Additional information: Clindamycin phosphate is slightly hygroscopic.
DRUG CENTRAL
3909
Created by admin on Wed Jul 05 22:50:27 UTC 2023 , Edited by admin on Wed Jul 05 22:50:27 UTC 2023
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY